The aim is to study pharmacokinetic profile of arotinoid trometamol(code name: FY-10) in mice.Blood concentrations of FY-10 were determined by HPLC-MS/MS using acitretin as internal standard 0.08, 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 h after i.v. (16 μg/kg) and 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 48.0 and 72.0 h after i.g. (4, 16 and 64 μg/kg) administration, at each time point with 8 mice; pharmacokinetic parameters were calculatedPlasma protein binding rates in vitro of FY-10(10, 20, 40 ng/mL) in plasma of mice were determinedZorbax Extend C18 column was used with mobile phase of mixture [methanol-acetonitrile(50:50)]-20 mmol/L ammonium acetate(pH 8.5)(85:15) at flow rate of 0.8 mL/min.Column temperature was 35°C and sample size was 40 μl.Mass condition was as follows: ion spray voltage of -3500 V, multiple reaction monitoring, neg. ion detection mode, m/z values ranging from 347->303 for FY-10 and 325->266 for acitretin.Linear range of FY-10 was 0.05-40.0 ng/mL (r=0.997 3) with average recovery of (50.6±3.1)%-(67.6±1.0)%.Pharmacokinetic parameters of FY-10 after low-dose, medium-dose and high-dose intragastric administration were as follows: AUC(0->infinity):17.09, 64.08 and 133.99 ng·h/mL; cmax:1.54, 5.27 and 15.30 ng/mL; t1/2:15.7, 18.7 and 16.7 h, resp.Those after i.v. administration were as follows: AUC(0->infinity):70.80 ng·h/mL; t1/2:22.1 h; absolute bioavailability of FY-10 was 91.9%.The plasma protein binding rates in vitro of FY-10 at low, medium and high concentrations were (97.9±0.3)%, (99.3±0.1)% and (98.5±0.5)%, resp.Pharmacokinetics process of FY-10 was in line with one-compartment model after i.g. administration and two-compartment model after i.v. administration.In vivo and in vitro trials of mice showed high bioavailability and plasma protein binding rate.